$400 savings end in:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
2026 Agenda: Day 2 - Tuesday 13 January - PT (Pacific Time, GMT-08:00)
This session will discuss how regulatory reforms, ready access to financing, and a rapidly evolving innovation ecosystem are transforming Asia into a leading destination for biotech growth. Join investors and industry leaders to explore the opportunities and strategies shaping the future of biopharma in this dynamic market.
Even as breakthroughs in biotech and therapeutics accelerate, access and equity remain out of reach for many. With the new administration introducing policy changes, regulatory shifts, and funding priorities, the question looms: are these moves helping to expand healthcare access, or inadvertently creating new barriers? Join investors, industry leaders, and policymakers to explore how these developments are reshaping the landscape—and what strategies can drive meaningful, equitable change.
- Emma Wheatley - Executive Director Access & Business Development, Coalition for Epidemic Preparedness Innovations (CEPI)
Learn how next-generation technologies—organoids, data-driven models, and high-throughput platforms—are redefining preclinical and clinical research. Explore with investors and industry leaders how these TechBio innovations are speeding up timelines, de-risking programs, and transforming the path to new therapies.
Explore cutting-edge advances in cell and gene therapies that reshape the treatment landscape and create new investment opportunities. This session highlights emerging technologies driving transformative therapeutics.
As blockbuster checkpoint inhibitors like Keytruda and Opdivo approach their patent cliffs, the strategic focus has shifted to what comes next. This panel will gather leaders from large pharma and innovative biotechs to discuss the new era of combination regimens. They will explore the science and strategy behind pairing established immunotherapies with next-generation modalities to create transformative outcomes for patients and drive the next wave of deal-making.
- Joel Sandler - Associate Partner, Ipsos Advisory Healthcare